SERAC1 Gene 3-methylglutaconic aciduria with deafness encephalopathy and Leigh-like syndrome Genetic Test
Test Name: SERAC1 Gene 3-methylglutaconic aciduria with deafness encephalopathy and Leigh-like syndrome Genetic Test
Components: Price: 4400.0 AED
Sample Condition: Blood or Extracted DNA or One drop Blood on FTA Card
Report Delivery: 3 to 4 Weeks
Method: NGS Technology
Test type: Metabolic Disorders
Doctor: General Physician
Test Department: Genetics
Pre Test Information: Clinical History of Patient who is going for SERAC1 Gene 3-methylglutaconic aciduria with deafness, encephalopathy, and Leigh-like syndrome NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with 3-methylglutaconic aciduria with deafness, encephalopathy, and Leigh-like syndrome.
Test Details: The SERAC1 gene is associated with a rare genetic disorder called 3-methylglutaconic aciduria with deafness, encephalopathy, and Leigh-like syndrome. This disorder is characterized by elevated levels of 3-methylglutaconic acid in the urine, along with symptoms such as deafness, encephalopathy (brain dysfunction), and a syndrome similar to Leigh syndrome, which is a progressive neurological disorder.
NGS (Next-Generation Sequencing) genetic testing refers to a high-throughput sequencing technology used to analyze multiple genes simultaneously. In the context of 3-methylglutaconic aciduria with deafness, encephalopathy, and Leigh-like syndrome, NGS genetic testing can be used to identify mutations or variations in the SERAC1 gene. This can help in confirming a diagnosis and providing information about the specific genetic cause of the disorder.
NGS genetic testing is a powerful tool that allows for the analysis of multiple genes in a single test, which can save time and resources compared to traditional genetic testing methods. It can also provide a more comprehensive understanding of the genetic basis of a disorder, enabling better management and treatment options for affected individuals.
| Test Name | SERAC1 Gene 3-methylglutaconic aciduria with deafness encephalopathy and Leigh-like syndrome Genetic Test |
|---|---|
| Components | |
| Price | 4400.0 AED |
| Sample Condition | Blood or Extracted DNA or One drop Blood on FTA Card |
| Report Delivery | 3 to 4 Weeks |
| Method | NGS Technology |
| Test type | Metabolic Disorders |
| Doctor | General Physician |
| Test Department: | Genetics |
| Pre Test Information | Clinical History of Patient who is going for SERAC1 Gene 3-methylglutaconic aciduria with deafness, encephalopathy, and Leigh-like syndrome NGS Genetic DNA Test A Genetic Counselling session to draw a pedigree chart of family members affected with 3-methylglutaconic aciduria with deafness, encephalopathy, and Leigh-like syndrome |
| Test Details | The SERAC1 gene is associated with a rare genetic disorder called 3-methylglutaconic aciduria with deafness, encephalopathy, and Leigh-like syndrome. This disorder is characterized by elevated levels of 3-methylglutaconic acid in the urine, along with symptoms such as deafness, encephalopathy (brain dysfunction), and a syndrome similar to Leigh syndrome, which is a progressive neurological disorder. NGS (Next-Generation Sequencing) genetic testing refers to a high-throughput sequencing technology used to analyze multiple genes simultaneously. In the context of 3-methylglutaconic aciduria with deafness, encephalopathy, and Leigh-like syndrome, NGS genetic testing can be used to identify mutations or variations in the SERAC1 gene. This can help in confirming a diagnosis and providing information about the specific genetic cause of the disorder. NGS genetic testing is a powerful tool that allows for the analysis of multiple genes in a single test, which can save time and resources compared to traditional genetic testing methods. It can also provide a more comprehensive understanding of the genetic basis of a disorder, enabling better management and treatment options for affected individuals. |
